Novo Nordisk upgrades despite sales and bottom line disappointments in Q2
Following six months where analysts had hoped for stronger performance, the pharmaceutical giant has raised its sales growth guidance for full-year 2022 to 12–16%.
by marketwire, translated by daniel pedersen
On Wednesday, Novo Nordisk surprised the market when it released its financial report for the first half of 2022 – the evening before it was scheduled to do so.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Novo Nordisk has twin successes with once-weekly insulin
For subscribers
